Swasthya Adhikar Manch v. Union of India

Last updated
Swasthya Adhikar Manch v. Union of India
Emblem of the Supreme Court of India.svg
Court Supreme Court of India
Full case nameSwasthya Adhikar Manch and Ors. versus Union of India &Ors..
Decided21 October 2013;8 years ago (2013-10-21) [1]

Swasthya Adhikar Manch v. Union of India was a 2013 court case in which Swasthya Adhikar Manch requested additional government regulation in the management of clinical trials. The court found in favor of that organization and ordered regulation.

One of the complaints was enrolling research participants without proper informed consent. [2]

Results of the ruling include that contract research organizations must register with the government, trials must define how they will give compensation to research participants in case of injury, researchers must report guidelines for safe use of the study drugs in advance of beginning the trial, and there must be draft rules defining what conditions must be met before a trial begins. [3]

Various regulatory changes followed the ruling. [4]

Any company seeking approval to do clinical trials has to report the risks and benefits to patients for the research. [5]

As a result of the ruling in 2014 India published new requirements for clinical trials. [6]

The Supreme Court reprimanded an organization for not compensating victims who were injured. [7]

Related Research Articles

Randomized controlled trial Form of scientific experiment

A randomized controlled trial is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.

Clinical trial Phase of clinical research in medicine

Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted.

In published academic research, publication bias occurs when the outcome of an experiment or research study biases the decision to publish or otherwise distribute it. Publishing only results that show a significant finding disturbs the balance of findings in favor of positive results. The study of publication bias is an important topic in metascience.

<i>The BMJ</i> Peer-reviewed medical journal

The BMJ is a weekly peer-reviewed medical trade journal, published by the trade union the British Medical Association (BMA). The BMJ has editorial freedom from the BMA. It is one of the world's oldest general medical journals. Originally called the British Medical Journal, the title was officially shortened to BMJ in 1988, and then changed to The BMJ in 2014. The journal is published by BMJ Publishing Group Ltd, a subsidiary of the British Medical Association (BMA). The editor-in-chief of The BMJ is Kamran Abbasi, who was appointed in January 2022.

Oseltamivir Antiviral medication used against influenza A and influenza B

Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B, the viruses that cause the flu. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. They recommend it to prevent infection in those at high risk, but not the general population. The Centers for Disease Control and Prevention (CDC) recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms of infection. It is taken by mouth, either as a pill or liquid.

In clinical trials, a surrogate endpoint is a measure of effect of a specific treatment that may correlate with a real clinical endpoint but does not necessarily have a guaranteed relationship. The National Institutes of Health (USA) defines surrogate endpoint as "a biomarker intended to substitute for a clinical endpoint".

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

<i>PLOS Medicine</i> Academic journal

PLOS Medicine is a peer-reviewed weekly medical journal covering the full spectrum of the medical sciences. It began operation on October 19, 2004, as the second journal of the Public Library of Science (PLOS), a non-profit open access publisher. All content in PLOS Medicine is published under the Creative Commons "by-attribution" license. To fund the journal, the publication's business model requires in most cases that authors pay publication fees. The journal was published online and in a printed format until 2005 and is now only published online. The journal's acting chief editor is Clare Stone, who replaced the previous chief editor, Larry Peiperl, in 2018.

The Declaration of Helsinki is a set of ethical principles regarding human experimentation developed originally in 1964 for the medical community by the World Medical Association (WMA). It is widely regarded as the cornerstone document on human research ethics.

A medical writer, also referred to as medical communicator, is a person who applies the principles of clinical research in developing clinical trial documents that effectively and clearly describe research results, product use, and other medical information. The medical writer develops any of the five modules of the Common Technical Document. The medical writers also ensure that their documents comply with regulatory, journal, or other guidelines in terms of content, format, and structure.

In medicine, a case report is a detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. Case reports may contain a demographic profile of the patient, but usually describe an unusual or novel occurrence. Some case reports also contain a literature review of other reported cases. Case reports are professional narratives that provide feedback on clinical practice guidelines and offer a framework for early signals of effectiveness, adverse events, and cost. They can be shared for medical, scientific, or educational purposes.

Dasatinib Chemical compound

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

Dabigatran Anticoagulant medication

Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests. It is taken by mouth.

Acronyms are very commonly used in healthcare settings. They are formed from the lead letters of words relating to medications, organisations, procedures and diagnoses. They come from both English and Latin roots. Acronyms have been described as jargon. and their use has been shown to impact the safety of patients in hospitals, owing to ambiguity and legibility.

National Alliance of People's Movements is an alliance of progressive people's organizations and movements in India. It is an umbrella organisation for a larger alliance integrating various civil society organisations and individuals working towards similar goals.

AllTrials

AllTrials is a project advocating that clinical research adopt the principles of open research. The project summarizes itself as "All trials registered, all results reported": that is, all clinical trials should be listed in a clinical trials registry, and their results should always be shared as open data.

The GRADE approach is a method of assessing the certainty in evidence and the strength of recommendations in health care. It provides a structured and transparent evaluation of the importance of outcomes of alternative management strategies, acknowledgment of patients and the public values and preferences, and comprehensive criteria for downgrading and upgrading certainty in evidence. It has important implications for those summarizing evidence for systematic reviews, health technology assessments, and clinical practice guidelines as well as other decision makers.

Clinical trials in India

Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.

Swasthya Adhikar Manch is a nonprofit organization in India which advocates for safety in clinical trials.

Covaxin Vaccine against COVID-19

Covaxin is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

References

  1. "Swasthya Adhikar Manch and Ors v. Union of India (UOI) and Ors".
  2. Roy Chaudhury, R.; Mehta, D. (2016). "Regulatory developments in the conduct of clinical trials in India". Global Health, Epidemiology and Genomics. 1: e4. doi: 10.1017/gheg.2015.5 . PMC   5870412 . PMID   29868198.
  3. Shukla, Anay; Baxi, Khushboo (20 January 2013). "Clinical Trials on Trial". Nishith Desai Associates.
  4. Chatterjee, S (2013). "Regulatory changes in conduct of clinical trials: a need for review". Indian Journal of Pharmacology. 45 (4): 323–4. doi:10.4103/0253-7613.114990. PMC   3757596 . PMID   24014903.
  5. Kay, M. (3 July 2014). "Indian Supreme Court demands clarity on clinical trial approvals". BMJ. 349: g4383. doi:10.1136/bmj.g4383. PMID   24994706. S2CID   37807701.
  6. Bagcchi, S. (15 September 2014). "India issues new requirements for clinical trial approval". BMJ. 349: g5648. doi:10.1136/bmj.g5648. PMID   25223241. S2CID   41507151.
  7. Pandey, Kundan (17 August 2015). "Drug trials: SC pulls up Centre for not compensating victims who suffered severe adverse effects". www.downtoearth.org.in.